Mandal · The international journal of neuropsychopharmacology 2024 · in vitro controlled experiment · n=?

Ketamine Prevents Inflammation-Induced Reduction of Human Hippocampal Neurogenesis via Inhibiting the Production of Neurotoxic Metabolites of the Kynurenine Pathway.

Cited 14 times in the scientific literature.

Level 5 - mechanism / opinion, no new human data

In vitro laboratory study using a cell line model without in vivo or clinical human data

PubMed 39297528 · doi:10.1093/ijnp/pyae041 · record verified 2026-08-29

What was done

In vitro experimental study using a human fetal hippocampal progenitor cell line (HPC0A07/03C). Cells were treated with inflammatory cytokines (interleukin-1beta [IL-1b, 10 ng/mL] or interleukin-6 [IL-6, 50 pg/mL]), alone or in combination with ketamine enantiomers (arketamine/R-ketamine, 400 nM; esketamine/S-ketamine, 400 nM) or conventional antidepressants (sertraline, 1 mM; venlafaxine, 1 mM). The authors assessed neurogenesis, apoptosis, downstream cytokine production, indoleamine 2,3-dioxygenase expression, and kynurenine production.

What was found

Both R-ketamine and S-ketamine prevented IL-1b- and IL-6-induced reductions in neurogenesis and increases in apoptosis, resembling the effects of sertraline and venlafaxine. R-ketamine selectively inhibited IL-1b-induced IL-2 and IL-13, as well as IL-6-induced IL-13. S-ketamine selectively inhibited IL-1b-induced TNF-alpha, as well as IL-6-induced IL-1b and IL-8. Both enantiomers prevented IL-1b-induced IDO expression and kynurenine production, but neither enantiomer prevented IL-6-induced kynurenine pathway activation. The abstract reported no numerical effect sizes or variance statistics.

Why it matters

This study provides mechanistic in vitro evidence that ketamine enantiomers protect human hippocampal progenitor cells from cytokine-driven neurogenic impairment, showing differential cytokine modulation and context-dependent engagement of the kynurenine pathway.

Limits

The study is restricted to an in vitro fetal cell line model and cannot replicate in vivo brain circuitry, systemic pharmacokinetics, or human clinical depression. No numerical measurements, variance estimates, or biological replicate sample sizes were reported in the abstract.

Cited by